Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Actuarial Approach01:20

Actuarial Approach

68
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
68
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

110
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
110
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

162
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
162
Cancer Survival Analysis01:21

Cancer Survival Analysis

334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Most prominent challenges in translational neuroscience and strategic solutions to bridge the gaps: Perspectives from an editorial board interrogation.

Exploration of neuroscience·2025
Same author

Case-Fatality Rate in Parkinson's Disease: A Nationwide Registry Study.

Movement disorders clinical practice·2024
Same author

The incidence and management of slipped capital femoral epiphysis: a population-based study.

Acta orthopaedica Belgica·2024
Same author

Exposure to systemic antibiotics in outpatient care and the risk of multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2023
Same author

Adult-Onset Neuroepidemiology in Finland: Lessons to Learn and Work to Do.

Journal of clinical medicine·2023
Same author

A severe neurodegenerative disease with Lewy bodies and a mutation in the glucocerebrosidase gene.

NPJ Parkinson's disease·2023

Related Experiment Video

Updated: Jun 13, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K

Stable excess mortality in a multiple sclerosis cohort diagnosed 1970-2010.

M-L Sumelahti1, A Verkko1, V Kytö2

  • 1Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

European Journal of Neurology
|September 11, 2024
PubMed
Summary

Disease-modifying treatments (DMTs) improve survival for people with multiple sclerosis (pwMS). However, relative life expectancy for pwMS has not improved over five decades, with male sex being a risk factor for death.

Keywords:
autoimmune diseasescase–control studiesdemyelinating diseasesepidemiologymortalitymultiple sclerosissurvivaltherapeutics

More Related Videos

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

57.9K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.4K

Related Experiment Videos

Last Updated: Jun 13, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

57.9K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.4K

Area of Science:

  • Neurology
  • Epidemiology
  • Clinical Research

Background:

  • Multiple sclerosis (MS) is linked to increased mortality rates.
  • Disease-modifying treatments (DMTs) show potential for improving survival in MS patients.

Purpose of the Study:

  • To investigate the long-term survival trends of people with MS (pwMS) in relation to diagnosis decade and DMT use.
  • To identify factors influencing mortality among pwMS.

Main Methods:

  • A regional MS database was linked with national registries for comprehensive data.
  • 1795 pwMS diagnosed between 1971-2010 were followed until 2019, with five matched controls per patient.
  • Interferon and glatiramer acetate were the DMTs analyzed.

Main Results:

  • Survival did not significantly differ across diagnosis decades.
  • Male sex, higher age at diagnosis, and primary progressive MS course were associated with poorer survival.
  • DMT use was significantly associated with better survival (p < 0.0001).

Conclusions:

  • Despite DMT benefits, the relative life expectancy for pwMS has not improved over five decades in Western Finland.
  • Male sex is an independent risk factor for mortality, though excess mortality is higher in women.
  • Further research and improved methods are needed to enhance survival rates for pwMS.